IDH1 Human

IDH1 is a soluble enzyme encoded by the IDH1 gene located on chromosome 2 in humans . The enzyme uses NADP+ as an electron acceptor, distinguishing it from other isocitrate dehydrogenases that use NAD+ . The human recombinant form of IDH1 is typically produced in E. coli and is available with a C-terminal 6-His tag for purification purposes .

Mutations in the IDH1 gene have been associated with various types of cancer, including gliomas and acute myeloid leukemia (AML). These mutations often result in a gain-of-function, leading to the production of an oncometabolite called 2-hydroxyglutarate (2-HG), which can contribute to tumorigenesis . IDH1 expression has also been correlated with poor survival in non-small cell lung cancer .

Recombinant human IDH1 is widely used in research to study its role in metabolism and cancer. It is also utilized in drug discovery efforts aimed at developing inhibitors for mutant IDH1 enzymes. The recombinant protein is typically supplied as a carrier-free formulation to avoid interference from other proteins, such as Bovine Serum Albumin (BSA) .

The recombinant human IDH1 protein is supplied as a 0.2 μm filtered solution in Tris, NaCl, Glycerol, Brij-35, and DTT. It is shipped with dry ice and should be stored at -70°C to maintain stability. The protein remains stable for six months from the date of receipt when stored at -70°C and for three months under sterile conditions after opening .

To measure the activity of recombinant human IDH1, an assay can be performed using a substrate mixture of NADP+ and isocitric acid. The enzyme’s activity is determined by its ability to oxidatively decarboxylate isocitrate to 2-oxoglutarate, with a specific activity of over 10,000 pmol/min/μg .